These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9653592)

  • 1. Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion. A case report.
    Meier M; Brand J; Standl E; Schnell O
    Diabetes Care; 1998 Jul; 21(7):1044-5. PubMed ID: 9653592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.
    Burge MR; Castillo KR; Schade DS
    Diabetes Care; 1997 Feb; 20(2):152-5. PubMed ID: 9118763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Clin Ther; 1997; 19(1):62-72. PubMed ID: 9083709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Guerci B; Meyer L; Sallé A; Charrié A; Dousset B; Ziegler O; Drouin P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2673-8. PubMed ID: 10443658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin.
    Tokuyama Y; Nozaki O; Kanatsuka A
    Diabetes Res Clin Pract; 2001 Dec; 54(3):209-12. PubMed ID: 11689276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
    Wilde MI; McTavish D
    Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR; Bell MA; Heyob JA; Storms SM
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM.
    Torlone E; Pampanelli S; Lalli C; Del Sindaco P; Di Vincenzo A; Rambotti AM; Modarelli F; Epifano L; Kassi G; Perriello G; Brunetti P; Bolli G
    Diabetes Care; 1996 Sep; 19(9):945-52. PubMed ID: 8875087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion.
    Wredling R; Liu D; Lins PE; Adamson U
    Diabete Metab; 1991; 17(5):456-9. PubMed ID: 1752346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.